Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2B | Q13224 | 8/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | PRKCZ | Q05513 | 3/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | AVPR2 | P30518 | 1/20 | 0.32 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18964518 | 1.00 | GRIN2B (0.38) | GRIN2BALDH1A1PRKCZHTTPOLB | |
| SCHEMBL18964714 | 0.92 | GRIN2B (0.43) | GRIN2BALDH1A1 | |
| SCHEMBL30219916 | 0.92 | ALDH1A1 (0.40) | GRIN2BALDH1A1PRKCZHTTPOLB | |
| SCHEMBL30219878 | 0.92 | GRIN2B (0.43) | GRIN2BALDH1A1 | |
| SCHEMBL18965065 | 0.92 | ALDH1A1 (0.40) | GRIN2BALDH1A1PRKCZHTTPOLB | |
| SCHEMBL18964711 | 0.90 | GRIN2B (0.40) | GRIN2BALDH1A1PRKCZHTTPOLB | |
| SCHEMBL30219973 | 0.90 | GRIN2B (0.40) | GRIN2BALDH1A1PRKCZHTTPOLB | |
| SCHEMBL18964795 | 0.89 | ALDH1A1 (0.39) | GRIN2BALDH1A1PRKCZHTTPOLB | |
| SCHEMBL30220106 | 0.89 | ALDH1A1 (0.39) | GRIN2BALDH1A1PRKCZHTTPOLB | |
| SCHEMBL18955880 | 0.89 | ALDH1A1 (0.39) | GRIN2BALDH1A1PRKCZHTTPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12162890-B2 | Heteroaromatic NMDA receptor modulators and uses thereof | NOVARTIS AG (CH) | 2024-12-10 | — | — | US | disclosed |
| US-20230023543-A1 | HETEROAROMATIC NMDA RECEPTOR MODULATORS AND USES THEREOF | NOVARTIS AG (CH) | 2023-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12162890-B2 | Heteroaromatic NMDA receptor modulators and uses thereof | GRIN2C, GRIN2A, GRIN1 | GRIN2B 5/4885ALDH1A1 1771/4885PRKCZ 2095/4885 |
| US-20230023543-A1 | HETEROAROMATIC NMDA RECEPTOR MODULATORS AND USES THEREOF | GRIN2C, GRIN2A, GRIN1 | GRIN2B 5/4885ALDH1A1 1771/4885PRKCZ 2095/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.